Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
US generic drugmaker ANI Pharmaceuticals says it has acquired the US rights for the antibiotic Vancocin (vancomycin HCl) 125mg and 250mg capsules from Shire, the Ireland-based pharma company that has just succumbed to a $53 billion takeover offer from AbbVie. 2 August 2014
Generics
Jordan-based drugmaker Hikma Pharmaceuticals says it has agreed with Ben Venue Laboratories, part of German family-owned drug major Boehringer Ingelheim, to acquire substantially all of the assets of its generic injectables manufacturing site in Bedford, Ohio, USA. 24 July 2014
Generics
Following a weekend of rumors and speculation, USA-based generics major Mylan and health care firm Abbott Laboratories this morning confirmed they have entered into a definitive agreement whereby Mylan will acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction. 14 July 2014
Generics
US provider of injectable drugs and infusion technologies Hospira says it has completed the acquisition of an active pharmaceutical ingredien manufacturing facility and an associated R&D facility from India’s Orchid Chemicals & Pharmaceuticals for around $218 million, after settling prior advances of about $30 million. 6 July 2014
Generics
Dubai Investments PJSC, the leading investment company listed on the Dubai financial market [DFM], has announced the divestment of 66% equity stake in its pharmaceutical subsidiary Globalpharma to French drug major Sanofi. 29 June 2014
Generics
Japan’s Meiji Seika Pharma revealed today that it intends to acquire all of the outstanding shares of Indian drugmaker Medreich, subsequent to which the company will become a subsidiary of Meiji Seika Pharma and will retain its name. 12 June 2014
Generics
USA-based Albany Molecular Research has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing for $110 million in cash. 2 June 2014
Generics
Jordon-based drugmaker Hikma Pharmaceuticals has signed an asset purchase agreement with Ben Venue Laboratories, a member of Germany’s Boehringer Ingelheim group, to acquire assets of Bedford Laboratories, its US generic injectables business. 28 May 2014
Generics
In the wake of a suspension of its proposed $4 billion acquisition of domestic rival Ranbaxy Laboratories (The Pharma Letter April 7) over potential “insider trading,” Indian drugmaker Sun Pharmaceutical Industries has said it will take "appropriate action." 5 May 2014
Generics
USA-based Endo International as entered into a definitive agreement to acquire Grupo Farmaceutico Somar, a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for an undisclosed cash consideration. 29 April 2014
Generics
The USA’s Abbott Laboratories is considering acquiring the 81.1 % stake in Veropharm, one of Russia’s largest drugmakers. According to sources in Veropharm, the deal is scheduled for completion for the end of summer. 23 April 2014
Generics
After a day of rumor and speculation about a takeover approach from US generic firm Mylan, Swedish drugmaker Meda issued a statement confirming that it has been contacted by Mylan regarding an indicative proposal to combine the two businesses. 6 April 2014
Generics
Pamplona Capital Management has as acquired a majority stake in privately-held US company Alvogen, which it says is one of the fastest growing generics companies in the pharmaceutical industry. 2 April 2014
Generics
After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached agreement to acquire US drugmaker Forest Laboratories in a cash and equity transaction valued at around $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares per Forest share). 18 February 2014
Generics
US privately-held Par Pharmaceutical has entered into a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals, a specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products, headquartered in New Jersey. 21 January 2014
Generics
US generics major Actavis plans to enter into an agreement with India’s Aurobindo Pharma for the latter to acquire Actavis' generics commercial operations in seven markets in Western Europe. No financial terms of the proposed transaction were revealed. 18 January 2014
Generics
China’s Shenzhen Hepalink Pharmaceutical has entered into a stock purchase agreement to acquire USA-based Scientific Protein Laboratories, a leading global, independent manufacturer and supplier of active pharmaceutical ingredients (APIs). 27 December 2013
Generics
Emerging US generic drugmaker ANI Pharmaceuticals says that it has acquired 31 previously marketed generic drug products from Israeli generics giant Teva Pharmaceutical Industries. 27 December 2013
Generics
Indian injectable generic firm Gland Pharma says it has reached an agreement under which Kohlberg Kravis Roberts & Co (KKR), a global investment firm, will acquire a minority stake in the company for around $200 million, including the entire stake held by Evolvence India Life Sciences Fund (EILSF), an existing private equity investor in Gland Pharma. 29 November 2013
Generics
US generics and specialty drugmaker Mylan (NYSE: MYL) $1.6-billion foreign direct investment proposal - aiming to acquire Indian pharma firm Strides Arcolab's (BO: 532532) Agila Specialties unit (The Pharma Letter February 28) - has finally seen the green light, reports the Hindustan Times. India's Prime Minister Manmohan Singh last Friday cleared the Strides Arcolab-Mylan deal, overruling the concerns raised by Department of Industrial Policy and Promotion (DIPP) and Ministry of Health (TPL July 9). 22 August 2013
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze